Search
for
Sort by
Research 121–150 of 198
- Androgenisierung
- Seasonal Variations in Public Interest in Dermatological Conditions in Türkiye: Google Trends Analysis
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
- Histopathological characterization of inflammatory interparietal involvement in frontal fibrosing alopecia
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Perbandingan Kadar Transforming Growth Factor-Beta 1 pada Platelet Rich Plasma dengan Metode Pure dan Buffy Coat pada Populasi Individu Sehat
- Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Dermatological manifestations and associated factors in patients with Graves\' disease in Dakar
- 530 A clinical comparison of photobiomodulation devices for the treatment of alopecia in all skin types
- Das polyzystische Ovarsyndrom: Aktuelle Evidenz und praktische Empfehlungen
- Prevalence of Skin Diseases in Pediatric Patients Admitted to Cerrahpaşa Medical Faculty Dermatology and Venereal Diseases Outpatient Clinic Between 2014-2017
- Androgenetic alopecia, hirsutism and hypertrichosis
- Exploring the molecular mechanism of Polygonum multiflorum in treating androgenic alopecia based on the methods of bioinformatics and molecular docking
- Cutaneous Manifestations of Lupus Erythematosus in Antananarivo (Madagascar)
- A Dermoscopic Clue for the Diagnosis of Traction Alopecia: Peripilar Keratin Casts: Case Report
- Antioxidants and Long Covid
- Antioxidants and Long Covid
- Vitamin D‐dependent rickets Type II with alopecia: two case reports and review of the literature
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Tissue distribution and hypotensive effects of minoxidil in normotensive rats.
- Platelet-Rich Plasma Treatment for Endocrine-Induced Alopecia and Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors: A Randomized, Controlled, Pilot Study
- 8483 Changes in kidney hemodynamics during gender-affirming hormone therapy in transgender individuals - findings from the KNIGHT pilot study